Merck KGaA completes acquisition of France's Theramex
Merck KGaA's French subsidiary, Merck-Lipha, says that itspreviously-announced acquisition of Theramex (Marketletter November 1) has been finalized. The German parent group claimed that the purchase will make it "a significant player in the strongly-growing women's health care markets." No financial details were disclosed.
Theramex, based in Monaco, is the French market leader in gynecology and sexual hormone products, and Merck believes that the firm, which will keep its name, has the potential for above-average growth in the European and global pharmaceutical markets. The company employs 485 people and is expected to generate sales of 700 million French francs ($109.1 million) in 1999.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze